Protalix BioTherapeuticsPLX
About: Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.
Employees: 213
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
880% more call options, than puts
Call options by funds: $98K | Put options by funds: $10K
139% more capital invested
Capital invested by funds: $3.52M [Q3] → $8.4M (+$4.88M) [Q4]
33% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 9
14% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 7
2% more funds holding
Funds holding: 44 [Q3] → 45 (+1) [Q4]
1.32% more ownership
Funds ownership: 4.65% [Q3] → 5.97% (+1.32%) [Q4]
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
1 analyst rating
HC Wainwright & Co. Raghuram Selvaraju 44% 1-year accuracy 24 / 54 met price target | 479%upside $15 | Buy Maintained | 3 Feb 2025 |
Financial journalist opinion
Based on 8 articles about PLX published over the past 30 days









